PSDV News 3.45 Psivida Corp (PSDV)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Psivida Corp (PSDV) 3.45 $PSDV

Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.

pSivida announces 26 September 2014 as the PDUFA date for ILUVIEN
M2 - Tue Apr 15, 5:51AM CDT
Drug delivery company pSivida (NasdaqGM SDV) (ASX VA.AX) declared on Monday that the US Food and Drug Administration (FDA) has set Prescription Drug User Fee Act (PDUFA) goal date of 26 September 2014 for ILUVIEN.

pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN(R)
Business Wire - Mon Apr 14, 6:04AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN(R) following the recent resubmission of the New Drug Application (NDA) by pSivida's licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA's October 2013 complete response letter.

pSivida CEO to Discuss Company's Sustained Release Delivery System for Biologics at Two Upcoming Conferences
Business Wire - Tue Apr 01, 9:09AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss pSivida's Tethadur(TM) technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.

pSivida Announces Resubmission of New Drug Application for ILUVIEN(R)
Business Wire - Thu Mar 27, 6:05AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe.

pSivida Corp. Announces $7.0 Million Investment by RA Capital
Business Wire - Thu Mar 13, 8:46AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that RA Capital has entered into a securities purchase agreement with the Company to invest approximately $7.0 million in a registered direct offering through the sale of a total of 1.7 million shares of the Company's common stock at a per share price of $4.11.

10-Q: PSIVIDA CORP.
Edgar Online - Wed Feb 12, 9:31AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

pSivida Announces ILUVIEN(R) for DME Accepted by National Health Service Scotland
Business Wire - Mon Feb 10, 8:05AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN(R) for use within the National Health Service (NHS) Scotland under a simple patient access scheme. ILUVIEN will be available in the NHS Scotland to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies in pseudophakic eyes (those that have undergone cataract surgery).

pSivida Corp. Reports Second Quarter 2014 Results
Business Wire - Fri Feb 07, 3:00PM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11
Business Wire - Thu Feb 06, 9:24AM CST
pSivida Corp. (NASDAQ SDV)(ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 16th Annual BioCEO & Investor Conference, being held at the Waldorf-Astoria Hotel in New York, Monday and Tuesday, February 10 and 11. Dr. Ashton will make his presentation on Tuesday, February 11 at 9:30 EST. A webcast of the presentation will be available at: http://www.veracast.com/webcasts/bio/ceoinves...464352.cfm or at the company's website: www.psivida.com. There will be a webcast replay available one hour after the conclusion of Dr. Ashton's presentation that day and it will be available until May 11, 2014.

Research and Markets: Commercial Construction in New Zealand to 2017: Market Forecast Report
Business Wire - Thu Feb 06, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfx4k6/commercial) has announced the addition of the "Commercial Construction in New Zealand to 2017: Market Forecast" report to their offering.

pSivida Corp Announces Second Quarter 2014 Financial Results Release Date and Conference Call Information
Business Wire - Thu Jan 30, 3:39PM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2014 will be released after the market close on Friday, February 7, 2014, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.

3 Stocks Under $10 Moving Higher
at The Street - Wed Jan 29, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Hot Stock: pSivida, Shares Gain 8.7% (PSDV)
Comtex SmarTrend(R) - Mon Jan 13, 10:16AM CST
pSivida (NASDAQ SDV) is one of today's best performing low-priced stocks, up 8.7% to $4.48 on 1.0x average daily volume. pSivida has traded 351,000 shares thus far today, vs. average volume of 340,000 shares per day. The stock has outperformed the Dow (8.7% to the Dow's -0.0%) and outperformed the S&P 500 (8.7% to the S&P's -0.0%) during today's trading.

pSivida Corp. Reports First Orders for ILUVIEN(R) Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance
Business Wire - Mon Jan 13, 6:13AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial orders of ILUVIEN(R) to several U.K. National Health Service (NHS) facilities and the first NHS patient has received ILUVIEN for the treatment of chronic diabetic macular edema (DME) insufficiently responsive to available therapies.

Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on Forest Laboratories, Oxygen Biotherapeutics, Alimera, pSivida and AcelRx
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

pSivida Corp. (PSDV) Jumps: Stock Up 32.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 20, 6:51AM CST
pSivida Corp. was a big mover last session, as its shares rose roughly 32% on the day.

Update on pSivida's Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 19, 2:30PM CST
pSivida announced that its partner Alimera Sciences has successfully conducted labeling discussions with the FDA for Iluvien for the treatment of Diabetic Macular Edema.

Opening Buzz: SolarCity Corp, 3D Systems Corporation, pSivida Corp, Alcatel Lucent SA
ACCESSWIRE - Thu Dec 19, 9:45AM CST
New York, December 19, 2013 / Accesswire / - Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for SolarCity Corp (NASDAQ:SCTY), 3D Systems Corporation (NYSE DD), pSivida Corp.(NASDAQ SDV), Alcatel Lucent SA (ADR) (NYSE:ALU).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 22

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 90

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
GFT's Banking Leader Tag Puts Execution Risks Into Focus

Updated Category News Views 39

A banking overhaul is where glossy slides go to die. That is why GFT Technologies being named a Leader in QKS Group's 2026 SPARK Matrix for Digital Banking Services deserves a little more attention than the usual analyst-firm trumpet blast. This is not a prize for making a pretty mobile app. The work described here runs through strategy, architecture, core-platform...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 51

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 197

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 100

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 60

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 21

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 194

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 13

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading

Top 5 Most Recently Viewed Articles

AXIA Time Launches New College Football Playoff Limited Edition

Updated Category News Views 81

Introducing AXIA Time's New College Football Playoff Collection AXIA Time is making waves with its expanded partnership with the College Football Playoff (CFP) and the launch of a fantastic new collection. Known for its high-quality craftsmanship, AXIA Time has introduced a series of limited edition, heirloom-quality watches specifically created for the 2025 College...

Continue Reading
Uphold Launches Staking Services for UK Users Amid Changes

Updated Category News Views 375

Uphold Introduces Staking Features for UK Customers Customers of Uphold can now take advantage of staking rewards on their crypto assets. This major shift comes after the UK Treasury amended the Financial Services and Markets Act, allowing crypto-asset service providers to offer staking services to individuals and businesses within the United Kingdom. Impact of Regulatory...

Continue Reading
ASDS Annual Conference: Elevating Dermatology Education for 2025

Updated Category News Views 196

Registration Now Open for 2025 ASDS Annual Conference The American Society for Dermatologic Surgery (ASDS) has announced the opening of registration for its highly anticipated annual meeting. This prestigious event gathers dermatologists and their staff for a four-day immersive experience aimed at improving skills and knowledge in dermatologic surgery. The conference will...

Continue Reading
Revolutionizing Order Management with OMS+ Cloud Solution

Updated Category News Views 212

DataXstream Unveils OMS+ Cloud Solution for Enhanced Order Management DataXstream LLC has rolled out its latest innovation, the OMS+ Cloud specifically designed for SAP S/4HANA Cloud Public Edition, aiming to transform how businesses manage their sales and order processes. Transforming Sales and Order Processes For more than a decade, OMS+ has been at the forefront of...

Continue Reading
Innovative Paper Towel Stand Redefines Hygiene and Convenience

Updated Category News Views 170

Revolutionary Design for Paper Towel Dispensing In a world where hygiene is paramount, a visionary inventor from Oakgrove has developed an innovative solution known as the Adjustable Paper Towel Stand. This unique accessory is designed to dispense paper towels one at a time, effectively minimizing contact with the entire roll, which can often lead to contamination and...

Continue Reading